The FDA has approved Kerendia (finerenone) to slow progression of chronic kidney disease (CKD) associated with type 1 diabetes (T1D). | Biotech And Pharma ...

A PHTI analysis found that virtual CKD management programs have little impact on disease progression or healthcare spending ...

Virtual chronic kidney disease (CKD) management solutions have no consistent impact on slowing disease progression or ...

Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce ...

Digital chronic kidney disease tools are falling short on their goals of improving patient outcomes and reducing costs, adding to the mixed results of digital health technology.

About 30% of adults with type 1 diabetes develop chronic kidney disease ...

Bayer receives US FDA approval for Kerendia, a selective, nsMRA to treat adult patients with CKD associated with type 1 diabetes: Berlin Friday, September 18, 2026, 15:00 Hrs [IST ...

Atrasentan received FDA approval for IgA nephropathy, reducing proteinuria by 36% and showing consistent efficacy across diverse patient groups. Value-based care programs significantly slowed CKD ...

A personalised, moderately restricted low-protein diet was feasible in patients with advanced chronic kidney disease (CKD), with over 60% adherence. Patients who chose and followed the diet had a ...

Increased physical activity may slow kidney function decline in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology ...

The FDA has approved finerenone as a therapy to lower urinary albumin-to-creatinine ratio among adults with chronic kidney ...

Approval of the nonsteroidal mineralocorticoid receptor antagonist provides the first new treatment option in over 30 years for kidney disease in adults with type 1 diabetes.